Penny stock player to review all options to try staying afloat after clinical trial fail
Adamis Pharmaceuticals is slowly tumbling down, and the biotech is looking at all its options.
After a Phase II/III trial failure last month that sent …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
